• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Rubius Therapeutics Inc.

    2/27/23 6:50:06 AM ET
    $RUBY
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $RUBY alert in real time by email
    S-8 POS 1 tm237887d4_s8pos.htm S-8 POS

    As filed with the Securities and Exchange Commission on February 27, 2023

     

    Registration No. 333-264814

    Registration No. 333-255942

    Registration No. 333-237103

    Registration No. 333-231478

    Registration No. 333-226226

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-264814

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-255942

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-237103

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-231478

     

    POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-226226

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    RUBIUS THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware 46-2688109
    (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)
       

    c/o Verdolino & Lowey, P.C.

    124 Washington Street, Suite 101

    Foxborough, Massachusetts

    02035
    (Address of Principal Executive Offices) (Zip Code)

     

    Rubius Therapeutics, Inc. Amended and Restated 2014 Stock Incentive Plan

    Rubius Therapeutics, Inc. 2018 Stock Option and Incentive Plan

    Rubius Therapeutics, Inc. 2018 Employee Stock Purchase Plan

    (Full title of the plans)

     

    Dannielle Appelhans

    Chief Executive Officer

    Rubius Therapeutics, Inc.

    c/o Verdolino & Lowey, P.C.

    124 Washington Street, Suite 101

    Foxborough, MA 02035

    (508) 543-1720

    (Name and address of agent for service and telephone number, including area code, of agent for service)

     

    Copies to:

     

    Jacqueline Mercier, Esq.

    Yasin Akbari, Esq.

    Goodwin Procter LLP

    100 Northern Avenue

    Boston, Massachusetts 02210

    (617) 570-1762

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act (Check one):

     

    Large accelerated filer   ¨   Accelerated filer   ¨
           
    Non-accelerated filer   ¨ (Do not check if a smaller reporting company)   Smaller reporting company   x
           
            Emerging growth company   ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

    DEREGISTRATION OF SECURITIES

     

    This Post-Effective Amendment No. 1 (“Post-Effective Amendment No. 1”), filed by Rubius Therapeutics, Inc., a Delaware corporation (the “Company”), removes from registration all shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”) registered under the following Registration Statements on Form S-8 filed by the Company (each a “Registration Statement,” and collectively, the “Registration Statements”) with the U.S. Securities and Exchange Commission (the “Commission”), pertaining to the registration of shares of Common Stock offered under certain employee benefit and equity plans and agreements:

     

      • Registration Statement on Form S-8 (No. 333-264814), filed with the Commission on May 10, 2022, pertaining to the registration of 3,152,231 shares of Common Stock of the Company, relating to the Company’s 2018 Stock Option and Incentive Plan (the “2018 Plan”).
         
      • Registration Statement on Form S-8 (No. 333-255942), filed with the Commission on May 10, 2021, pertaining to the registration of 2,431,609 shares of Common Stock of the Company, relating to the 2018 Plan.
         
      • Registration Statement on Form S-8 (No. 333-237103), filed with the Commission on March 12, 2020, pertaining to the registration of 3,200,649 shares of Common Stock of the Company, relating to the 2018 Plan.
         
      • Registration Statement on Form S-8 (No. 333-231478), filed with the Commission on May 15, 2019, pertaining to the registration of 3,169,393 shares of Common Stock of the Company, relating to the Company’s 2018 Plan and 2018 Employee Stock Purchase Plan (the “2018 ESPP”).
         
      • Registration Statement on Form S-8 (No. 333-226226), filed with the Commission on July 18, 2018, pertaining to the registration of 18,621,525 shares of Common Stock of the Company, relating to the 2018 Plan, 2018 ESPP, and the Company’s Amended and Restated 2014 Stock Incentive Plan.

     

    As previously disclosed in a Form 8-K filed with the Commission on February 22, 2023, the board of directors of the Company (the “Board”) approved a plan of liquidation and dissolution of the Company (the “Plan of Dissolution”), subject to the approval of the Company’s stockholders. As a result of the proposed dissolution, the Company has terminated all offerings of its securities pursuant to its existing registration statements, including the Registration Statements. The Company hereby terminates the effectiveness of the Registration Statements and removes and withdraws from registration all securities of the Company registered under the Registration Statements that remain unsold as of the date hereof.

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing this Post-Effective Amendment No. 1 to the Registration Statements on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Foxborough in the Commonwealth of Massachusetts, on February 27, 2023.

     

      RUBIUS THERAPEUTICS, INC.
         
      By: /s/ Dannielle Appelhans
        Name: Dannielle Appelhans
        Title:

    Chief Executive Officer

    (Principal Executive Officer)

     

    Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 1 to the Registration Statements on Form S-8 has been signed by the following person in the capacity and on the date indicated.

     

    Signatures   Capacity   Date

     

    /s/ Pablo Cagnoni

    Pablo Cagnoni

     

     

    Director

     

     

    February 27, 2023

     

    *

    Catherine Sohn

     

     

    Director

     

     

    February 27, 2023

     

    *

    Jonathan R. Symonds

     

     

    Director

     

     

    February 27, 2023

     

     

    * By: /s/ Pablo Cagnoni  
      Pablo Cagnoni  
      Attorney-in-Fact  

     

     

     

    Get the next $RUBY alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RUBY

    DatePrice TargetRatingAnalyst
    9/13/2022Buy → Neutral
    Guggenheim
    2/25/2022$14.00 → $5.00Market Perform
    SVB Leerink
    11/9/2021$20.00 → $14.00Market Perform
    SVB Leerink
    10/19/2021$25.00 → $22.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $RUBY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

      Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of

      11/2/22 4:01:00 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform

      Dr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform.  www.alltrna.com. (PRNewsfoto/Alltrna)" alt="Alltrna unlocks tRNA biology to correct disease. The company's platform incorpo

      10/17/22 9:00:00 AM ET
      $DNLI
      $EVLO
      $FHTX
      $MCRB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Cellarity Announces Close of $121 Million Series C Financing

      Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are created, announced today the completion of a $121 million Series C financing, bringing its total funding raised to date to $274 million. In addition to participation by Flagship Pioneering and other Series B investors, four new investors participated, including Kyowa Kirin Co. Ltd. and Hanwha Impact Partners. The proceeds of the financing will be used to grow Cellarity's talent base, strengthen its platform, and advance its pipeline toward the clinic. "We welcome our new investors and appreciate the continued support of our current investors," said Fabrice Chouraqui, PharmD, CEO of Cellarit

      10/4/22 7:00:00 AM ET
      $DNLI
      $EVLO
      $FHTX
      $MCRB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $RUBY
    Leadership Updates

    Live Leadership Updates

    See more
    • Rubius Therapeutics Announces Process to Explore Strategic Alternatives and Leadership Changes

      Dannielle Appelhans to Become President and Chief Executive Officer Pablo J. Cagnoni, M.D., Appointed Chair of the Board of Directors CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that it has initiated a process to explore a range of strategic alternatives to maximize shareholder value and plans to engage an investment bank to act as a strategic advisor for this process. Strategic alternatives that will be evaluated include the sale of all or part of

      11/2/22 4:01:00 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alltrna Appoints Caroline Kӧhrer, Ph.D., Vice President, Discovery Platform

      Dr. Kӧhrer has more than 25 years of RNA research and development experience, including pioneering novel RNA-based technologies into new drug candidates and deciphering transfer RNA (tRNA) biology CAMBRIDGE, Mass., Oct. 17, 2022 /PRNewswire/ -- Alltrna, a Flagship Pioneering company unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, today announced the appointment of Caroline Kӧhrer, Ph.D., as Vice President, Discovery Platform.  www.alltrna.com. (PRNewsfoto/Alltrna)" alt="Alltrna unlocks tRNA biology to correct disease. The company's platform incorpo

      10/17/22 9:00:00 AM ET
      $DNLI
      $EVLO
      $FHTX
      $MCRB
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • HotSpot Therapeutics Appoints Jose Carmona to Board of Directors

      BOSTON, July 19, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Jose "Pepe" Carmona to its Board of Directors. Mr. Carmona brings over 20 years of leadership experience in the biopharmaceutical industry across a range of roles and therapeutic areas. "We are thrilled to welcome Pepe to our Board of Directors," said Jonathan Montagu, Co-Founder and Chief Executive Officer of HotSpot Thera

      7/19/22 7:00:00 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Appelhans Dannielle sold $1,323 worth of shares (10,385 units at $0.13), closing all direct ownership in the company

      4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)

      2/27/23 6:08:34 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Cagnoni Pablo J sold $2,112 worth of shares (8,448 units at $0.25), decreasing direct ownership by 11% to 66,082 units to cover withholding tax

      4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)

      2/1/23 9:41:05 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Appelhans Dannielle converted options into 7,500 shares and sold $970 worth of shares (3,878 units at $0.25), increasing direct ownership by 54% to 10,385 units to satisfy withholding tax

      4 - Rubius Therapeutics, Inc. (0001709401) (Issuer)

      2/1/23 9:40:03 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    SEC Filings

    See more
    • SEC Form 15-12G filed by Rubius Therapeutics Inc.

      15-12G - Rubius Therapeutics, Inc. (0001709401) (Filer)

      4/10/23 4:17:29 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rubius Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - Rubius Therapeutics, Inc. (0001709401) (Filer)

      4/6/23 5:11:23 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 25 filed by Rubius Therapeutics Inc.

      25 - Rubius Therapeutics, Inc. (0001709401) (Filer)

      3/28/23 4:23:38 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    Financials

    Live finance-specific insights

    See more
    • Rubius Therapeutics to Announce Second Quarter 2022 Financial Results

      CAMBRIDGE, Mass., July 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report second quarter financial results on Tuesday, August 9, 2022, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius Therapeutics Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeuti

      7/26/22 8:00:00 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rubius Therapeutics to Announce First Quarter 2022 Financial Results

      CAMBRIDGE, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to report first quarter financial results on Tuesday, May 10, 2022, before market open. The company will not be hosting a teleconference in conjunction with its financial results press release. About Rubius TherapeuticsRubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™.

      4/26/22 8:00:00 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability

      Best Responses Include Partial Responses in Certain Patients with Non-Small Cell Lung Cancer, Metastatic Anal Cancer and Metastatic Uveal Melanoma with No Treatment-Related Grade 3/4 Adverse Events or Dose-Limiting Toxicities as of the Cutoff Date Expanding Ongoing Phase 1 Arm of RTX-240 + Pembrolizumab to Focus on Non-Small Cell Lung Cancer and Renal Cell Carcinoma Management to Host Conference Call Today at 1:15 p.m. EDT to Discuss Clinical Data and Clinical Development Next Steps for RTX-240 CAMBRIDGE, Mass., April 08, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (NASDAQ:RUBY), a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create

      4/8/22 1:00:00 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

      SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)

      4/10/23 9:37:13 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

      SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)

      3/3/23 11:28:09 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Rubius Therapeutics Inc. (Amendment)

      SC 13G/A - Rubius Therapeutics, Inc. (0001709401) (Subject)

      2/14/23 1:00:53 PM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $RUBY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rubius Therapeutics downgraded by Guggenheim

      Guggenheim downgraded Rubius Therapeutics from Buy to Neutral

      9/13/22 10:44:26 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Rubius Therapeutics with a new price target

      SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $5.00 from $14.00 previously

      2/25/22 10:14:06 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SVB Leerink reiterated coverage on Rubius Therapeutics with a new price target

      SVB Leerink reiterated coverage of Rubius Therapeutics with a rating of Market Perform and set a new price target of $14.00 from $20.00 previously

      11/9/21 3:52:26 AM ET
      $RUBY
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care